In an interview published by Techcouver, CEO Dan Wattier discusses how 3C Therapeutics is working with Variational AI to explore generative AI for the design of new cancer therapies.
Read More
News
Mitacs Accelerate supports process development for 3C Therapeutics’ DAC research
On June 22, 2026, Mitacs Accelerate awarded support for a research collaboration between 3C Therapeutics and Professor David Perrin’s laboratory at the University of British Columbia.
Read More3C Therapeutics featured in BioCentury
BioCentury’s Emerging Company Profile covers 3C’s modular approach to degrader-antibody conjugates.
Read MoreVancouver-based 3C Therapeutics to apply Variational AI’s Enki™ platform to ligand design for proprietary TriCore DAC platform under Innovate BC’s Integrated Marketplace program
The collaboration applies Variational AI’s Enki platform to ligand design for 3C Therapeutics’ TriCore DAC platform, with support from Innovate BC’s Integrated Marketplace program.
Read MoreFoundational patent application filed for TriCore
On November 14, 2025, a U.S. provisional patent application was filed seeking protection for the TriCore platform and its use in degrader-antibody conjugates.
Read MoreMitacs Accelerate supports 3C Therapeutics–UBC research collaboration
On October 9, 2025, Mitacs Accelerate awarded support for a research collaboration between 3C Therapeutics and Professor David Perrin’s laboratory at the University of British Columbia.
Read More3C Therapeutics receives NRC IRAP support for degrader-antibody conjugate research
On July 15, 2025, 3C Therapeutics was approved for financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop and characterize degrader-antibody conjugates using its TriCore platform.
Read More3C Therapeutics licenses TriCore technology from UBC and iProgen
Under an agreement dated April 29, 2025, 3C Therapeutics holds an exclusive, worldwide license from the University of British Columbia and iProgen Biotech Inc. to develop and commercialize the technology underlying its TriCore platform.
Read MoreUpcoming events
Nov
3–4
2026
Presenting
3C Therapeutics to present at Invest in BC 2026
Vancouver Convention Centre West
3C Therapeutics has been selected to present at Invest in BC 2026. Contact us to arrange a meeting during the conference.
Get in touch
Contact 3C Therapeutics to discuss investment, partnering opportunities or scientific collaborations.